Specialization
pharmacometrics, physiologically-based pharmacokinetic modeling, neuro-oncology, personalized dosing, tyrosine kinase inhibitors
Focus of research
My research is focused on physiologically-based pharmacokinetic (PBPK) modeling of anti-cancer agents to guide personalized dosing in patients with brain tumors. By applying PBPK-modeling, drug concentrations in the brain tumor target site can be predicted, which can inform the design of appropriate dosing regimens. My main focus is on the treatment of both primary and metastasized brain tumors with tyrosine kinase inhibitors.
PBPK-modeling requires input on both drug and physiological system parameters. Clinical methods including MRI and PET imaging techniques can inform us on physiological aspects of the blood-brain-barrier and the distribution of the drug to the brain. Translational approaches can be used to incorporate parameters from in vitro and in vivo animal studies that are not accessible from clinical studies.